HC Wainwright & Co. Reiterates Buy on Galectin Therapeutics, Maintains $11 Price Target
Portfolio Pulse from Benzinga Newsdesk
HC Wainwright & Co. analyst Ed Arce has reiterated a Buy rating on Galectin Therapeutics (NASDAQ:GALT) and maintained an $11 price target.

April 09, 2024 | 3:57 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
HC Wainwright & Co. reaffirms a Buy rating on Galectin Therapeutics with a steady $11 price target.
The reiteration of a Buy rating and maintenance of an $11 price target by a reputable analyst firm like HC Wainwright & Co. is likely to instill confidence among investors and could lead to a positive short-term impact on Galectin Therapeutics' stock price. The analyst's endorsement serves as a strong signal of the company's potential value and growth prospects.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100